Cargando…

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype

Detalles Bibliográficos
Autores principales:	Lee, Alexander, Kanuri, Navya, Zhang, Yuanhao, Sayuk, Gregory S., Li, Ellen, Ciorba, Matthew A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501741/ https://www.ncbi.nlm.nih.gov/pubmed/26173109 http://dx.doi.org/10.1371/journal.pone.0133098

Ejemplares similares

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
por: Huang, Qian, et al.
Publicado: (2018)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
por: Duan, Zhenzhen, et al.
Publicado: (2020)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

IDO-GCN2 and autophagy in inflammation
por: McGaha, Tracy L.
Publicado: (2015)

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021)

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

Correction: Smek1 deficiency exacerbates experimental autoimmune encephalomyelitis by activating proinflammatory microglia and suppressing the IDO1-AhR pathway
por: Duan, Ruo-Nan, et al.
Publicado: (2023)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis
por: Williams, Richard O.
Publicado: (2013)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
por: Huang, Yi-Shu, et al.
Publicado: (2020)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia
por: Chilosi, Marco, et al.
Publicado: (2022)

Correction: HIV-1 Tat Protein Induces the Production of IDO in Human Monocyte Derived-Dendritic Cells through a Direct Mechanism: Effect on T Cells Proliferation
por: Planès, Rémi, et al.
Publicado: (2013)

Correction: The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model
por: Lee, Young Eun, et al.
Publicado: (2016)

New Insights into IDO Biology in Bacterial and Viral Infections
por: Schmidt, Susanne V., et al.
Publicado: (2014)

Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
por: Wainwright, Derek A., et al.
Publicado: (2013)

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
por: Merlo, Lauren M.F., et al.
Publicado: (2016)

IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020)

The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
por: Kashi, Alex A., et al.
Publicado: (2019)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

IDO/kynurenine pathway in cancer: possible therapeutic approaches
por: Abd El-Fattah, Eslam E.
Publicado: (2022)

An adverse tumor-protective effect of IDO1 inhibition
por: Kenski, Juliana C.N., et al.
Publicado: (2023)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

AhR-Mediated, Non-Genomic Modulation of IDO1 Function
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

(Acetylacetonato)dibromido[2,2-diphenylhydrazin-1-ido(1−)][2,2-diphenylhydrazin-1-ido(2−)]molybdenum(VI)
por: Bustos, Carlos, et al.
Publicado: (2011)

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v3667olh0rdmoposqo1pu4n9ij